RegenLab USA, which develops regenerative medication gadgets and biomaterials, filed on Friday with the SEC to boost as much as $35 million in an preliminary public providing.

RegenLab develops and manufactures single-use gadgets that put together autologous platelet-rich plasma (PRP), alone or mixed with hyaluronic acid (HA), on the level of care. Its merchandise are utilized in musculoskeletal, wound care, aesthetic, and ladies’s well being settings. The corporate’s two essential merchandise are RegenKit, a PRP preparation package, and Mobile Matrix, a PRP-HA mixture for knee osteoarthritis. Most merchandise are CE-marked in Europe, and several other RegenKit configurations, together with a wound gel coated by Medicare, are FDA-cleared within the US. Mobile Matrix shouldn’t be but accredited within the US and stays within the PMA course of. Based in Switzerland in 2003, the corporate runs manufacturing websites in Switzerland, France, and New Jersey, and sells via direct gross sales forces and distributors in about 90 nations.

The Jersey Metropolis, NJ-based firm was based in 2003 and booked $54 million in income for the 12 months ended June 30, 2026. It plans to listing on the Nasdaq below the image RGNA. RegenLab USA filed confidentially on October 20, 2025. StoneX Monetary is the only real bookrunner on the deal.